Hikma Pharmaceuticals PLC

LSE:HIK Rapporto sulle azioni

Cap. di mercato: UK£4.2b

Hikma Pharmaceuticals Gestione

Gestione criteri di controllo 2/4

Hikma Pharmaceuticals Il CEO è Riad Mishlawi, nominato in Sep2023, e ha un mandato di 1.17 anni. la retribuzione annua totale è $ 1.55M, composta da 21.5% di stipendio e 78.5% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.06% delle azioni della società, per un valore di £ 2.50M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.2 anni e 5.4 anni.

Informazioni chiave

Riad Mishlawi

Amministratore delegato

US$1.6m

Compenso totale

Percentuale dello stipendio del CEO21.5%
Mandato del CEO1.2yrs
Proprietà del CEO0.06%
Durata media del management1.2yrs
Durata media del Consiglio di amministrazione5.4yrs

Aggiornamenti recenti sulla gestione

Recent updates

Hikma Pharmaceuticals PLC's (LON:HIK) P/E Is On The Mark

Nov 11
Hikma Pharmaceuticals PLC's (LON:HIK) P/E Is On The Mark

Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?

Oct 24
Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?

Hikma Pharmaceuticals PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Aug 11
Hikma Pharmaceuticals PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Hikma Pharmaceuticals PLC (LON:HIK) Shares Could Be 36% Below Their Intrinsic Value Estimate

Aug 01
Hikma Pharmaceuticals PLC (LON:HIK) Shares Could Be 36% Below Their Intrinsic Value Estimate

Is Hikma Pharmaceuticals PLC (LON:HIK) Trading At A 29% Discount?

Apr 24
Is Hikma Pharmaceuticals PLC (LON:HIK) Trading At A 29% Discount?

Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?

Apr 02
Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?

Hikma Pharmaceuticals PLC's (LON:HIK) Share Price Matching Investor Opinion

Feb 25
Hikma Pharmaceuticals PLC's (LON:HIK) Share Price Matching Investor Opinion

Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?

Dec 27
Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?

An Intrinsic Calculation For Hikma Pharmaceuticals PLC (LON:HIK) Suggests It's 43% Undervalued

Dec 12
An Intrinsic Calculation For Hikma Pharmaceuticals PLC (LON:HIK) Suggests It's 43% Undervalued

Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet

Sep 19
Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet

Calculating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)

Sep 01
Calculating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)

Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?

Jun 21
Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?

Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 28% Above Its Share Price

Jun 02
Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 28% Above Its Share Price

Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet

Mar 14
Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet

Calculating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)

Feb 21
Calculating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)

Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?

Sep 27
Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?

Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 19% Below Its Share Price

Jun 24
Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 19% Below Its Share Price

These 4 Measures Indicate That Hikma Pharmaceuticals (LON:HIK) Is Using Debt Reasonably Well

Jun 06
These 4 Measures Indicate That Hikma Pharmaceuticals (LON:HIK) Is Using Debt Reasonably Well

Here's Why Hikma Pharmaceuticals (LON:HIK) Can Manage Its Debt Responsibly

Feb 26
Here's Why Hikma Pharmaceuticals (LON:HIK) Can Manage Its Debt Responsibly

Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 92% Above Its Share Price

Dec 01
Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 92% Above Its Share Price

Is Hikma Pharmaceuticals (LON:HIK) Using Too Much Debt?

Nov 11
Is Hikma Pharmaceuticals (LON:HIK) Using Too Much Debt?

Is There An Opportunity With Hikma Pharmaceuticals PLC's (LON:HIK) 32% Undervaluation?

Sep 02
Is There An Opportunity With Hikma Pharmaceuticals PLC's (LON:HIK) 32% Undervaluation?

Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?

Aug 09
Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?

Hikma Pharmaceuticals PLC (LON:HIK) Shares Could Be 26% Below Their Intrinsic Value Estimate

May 21
Hikma Pharmaceuticals PLC (LON:HIK) Shares Could Be 26% Below Their Intrinsic Value Estimate

Hikma Pharmaceuticals (LON:HIK) Seems To Use Debt Quite Sensibly

May 03
Hikma Pharmaceuticals (LON:HIK) Seems To Use Debt Quite Sensibly

It's Unlikely That Hikma Pharmaceuticals PLC's (LON:HIK) CEO Will See A Huge Pay Rise This Year

Apr 16
It's Unlikely That Hikma Pharmaceuticals PLC's (LON:HIK) CEO Will See A Huge Pay Rise This Year

How Does Hikma Pharmaceuticals PLC (LON:HIK) Stand Up To These Simple Dividend Safety Checks?

Apr 13
How Does Hikma Pharmaceuticals PLC (LON:HIK) Stand Up To These Simple Dividend Safety Checks?

Hikma Pharmaceuticals PLC (LON:HIK) Looks Interesting, And It's About To Pay A Dividend

Mar 14
Hikma Pharmaceuticals PLC (LON:HIK) Looks Interesting, And It's About To Pay A Dividend

Hikma Pharmaceuticals PLC Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Feb 28
Hikma Pharmaceuticals PLC Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Riad Mishlawi rispetto agli utili di Hikma Pharmaceuticals?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2024n/an/a

US$285m

Mar 31 2024n/an/a

US$238m

Dec 31 2023US$2mUS$333k

US$190m

Compensazione vs Mercato: La retribuzione totale di Riad ($USD 1.55M ) è inferiore alla media delle aziende di dimensioni simili nel mercato UK ($USD 3.23M ).

Compensazione vs guadagni: Dati insufficienti per confrontare la retribuzione di Riad con le performance aziendali.


AMMINISTRATORE DELEGATO

Riad Mishlawi (60 yo)

1.2yrs

Mandato

US$1,552,833

Compensazione

Mr. Riad Ali Mishlawi serves as Chief Executive Officer of Hikma Pharmaceuticals PLC since September 01, 2023 and serves as its Director since September 01, 2023. He had been the President of Injectables s...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Said Samih Darwazah
Executive Chairman17.3yrsUS$3.57m0.38%
£ 16.0m
Riad Mishlawi
CEO & Director1.2yrsUS$1.55m0.060%
£ 2.5m
Mazen Samih Darwazah
Executive Vice Chairman & President of MENA19.2yrsUS$2.84m0.63%
£ 26.1m
Khalid Waleed Al Nabilsi
Chief Financial Officer13.8yrsNessun dato0.20%
£ 8.4m
Patricia Bousfield
Chief Information Officerno dataNessun datoNessun dato
Guy Featherstone
Associate Director of Investor Relationsno dataNessun datoNessun dato
Samuel Park
General Counselno dataNessun datoNessun dato
Bassam Wael Kanaan
Executive Vice President of Corporate Development and M&A10.7yrsNessun dato0.26%
£ 10.7m
Hussein Arkhagha
Chief People Officer1.2yrsNessun datoNessun dato
Susan Ringdal
Executive Vice President of Strategic Planning & Global Affairs6.8yrsNessun datoNessun dato
William Larkins
President of Injectables Business1.2yrsNessun datoNessun dato
Julie Hill
Senior Vice President of Corporate Quality Compliance/Health & Safetyless than a yearNessun datoNessun dato

1.2yrs

Durata media

60yo

Età media

Gestione esperta: Il team dirigenziale di HIK non è considerato esperto (durata media 1.2 anni), il che suggerisce un nuovo team.


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Said Samih Darwazah
Executive Chairman17.3yrsUS$3.57m0.38%
£ 16.0m
Riad Mishlawi
CEO & Director1.2yrsUS$1.55m0.060%
£ 2.5m
Mazen Samih Darwazah
Executive Vice Chairman & President of MENA19.2yrsUS$2.84m0.63%
£ 26.1m
Victoria Hull
Senior Independent Non-Executive Director2yrsUS$149.27kNessun dato
Mary Henderson
Independent Non-Executive Director8.1yrsUS$176.38k0.0032%
£ 132.8k
John Castellani
Independent Non-Executive Director8.7yrsUS$159.69k0.0016%
£ 65.6k
Mohammed Ali Khaldoun Al-Husry
Non-Executive Director19.1yrsUS$116.72k0.52%
£ 21.8m
Douglas Hurt
Independent Non-Executive Director4.5yrsUS$149.85k0.0020%
£ 84.3k
Deneen Vojta
Independent Non-Executive Director2yrsUS$127.05k0.00045%
£ 18.7k
Cynthia Flowers
Independent Non-Executive Director5.4yrsUS$134.68k0.00050%
£ 20.8k
Nabil Rizk
Chairman of West-ward Pharmaceuticalsno dataNessun datoNessun dato
Laura Balan
Independent Non-Executive Director2.1yrsUS$124.98kNessun dato

5.4yrs

Durata media

66yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di HIK sono considerati esperti (durata media dell'incarico 5.4 anni).